NO_LONGER_AVAILABLENCT03363334
Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP
Studying Immune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rigel Pharmaceuticals
- Principal Investigator
- Anne-Marie Duliege, M.D.Rigel Pharmaceuticals, Inc., Chief Medical Officer
- Intervention
- Fostamatinib disodium 100 mg(drug)
- Eligibility
- 18 years · All sexes
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03363334 on ClinicalTrials.govOther trials for Immune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07206758Phase I Study of SHR-2173 Injection in Patients With Primary Immune ThrombocytopeniaGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE1NCT07083960OM336 in Autoimmune CytopeniasOuro Medicines
- RECRUITINGPHASE4NCT07133659Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot StudyAl-Mustansiriyah University
- RECRUITINGPHASE1NCT06943937A Clinical Study of YTS109 Cell in R/R Systemic Lupus ErythematosusChina Immunotech (Beijing) Biotechnology Co., Ltd.
- RECRUITINGNCT06727669Longitudinal Cohort of Thrombosis and Hemostasis DiseasesPeking University People's Hospital
- RECRUITINGPHASE2NCT06281327Avatrombopag in the Treatment of Pediatric Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China
- ACTIVE NOT RECRUITINGPHASE2NCT06199089A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune ThrombocytopeniaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06094881A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China